• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CHM

CHIMERIC THERAPEUTICS LIMITED - Charts / Financials

0.00% ! 0.2¢
Market Cap $8.837M  !
Healthcare Biotechnology
Add to My Watchlist

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company,... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.05pm 10/04/2026 (20 minute delay) ?
Day
Open 0.2¢   Day High 0.2¢   Day Low 0.2¢
Daily Volume 276000
Bids   Sellers
Number Price Volume   Number Price Volume
0 0.1¢ 265836645   0 0.2¢ 40805564

Directors & Senior Management

Mr. Aaron Laurita Chief Financial Officer
Dr. Agathe Bourgogne Head of Manufacturing
Dr. Bradley Glover Non-Executive Chair
Dr. David G. Maloney Member of Cellular Immunotherapy Scientific Advisory Board
Mr. Eric M. Sullivan Non-Executive Director
Dr. Eric Smith Member of Cellular Immunotherapy Scientific Advisory Board
Prof. Henry Miles Prince Non-Executive Director
Dr. Lesley Russell Cooper Non-Executive Director
Dr. Michael R. Bishop Member of Cellular Immunotherapy Scientific Advisory Board
Mr. Nathan Jong Joint Company Secretary
Mr. Philip Allen Hains Non-Executive Director
Dr. Rebecca McQualter Chief Executive Officer
Dr. Stanley Frankel Member of Cellular Immunotherapy Scientific Advisory Board
Dr. Stephanie H. Astrow Chief Scientific Officer
Dr. Yin Li Member of Cellular Immunotherapy Scientific Advisory Board

Data source: ADVFN

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.837M
Open High Low Volume
0.2¢ 0.2¢ 0.2¢ 276K

Buyers (Bids)

Vol. Price($)
265836645 0.1¢
 

Sellers (Offers)

Price($) Vol.
0.2¢ 40805564
Last trade - 15.05pm 10/04/2026 (20 minute delay) ?

Top Stories

Invictus up over +29% on plans to drill key Zimbabwe well

Invictus Energy has been granted a key environmental approval as it progresses drilling plans for its Cabora Bassa Basin asset in Zimbabwe.
Introducing Prairie Lithium: Saskatchewan's permitted lithium project ready to scale We've spoken to Prairie Lithium founder Zach Maurer about the explorer's overall mission, right after Macquarie's bullish note on lithium.
Elixir fast-tracks Taroom Trough pipeline plans, hot on the heels of QLD gov't calling for action Elixir Energy is fast-tracking plans to bring the significant petroleum reserves in the Taroom Trough to market.
HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre. In this segment, we wrap up the stocks and company announcements you were watching this week on Australia’s #1 finance website. Let’s get straight into it, star...
US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27 AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and founder and managing director Hartley Atkinson believes it’s only going to get better as the growing Oz-based multinational pharmaceutical compan...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.